The Danish Medicines Agency has published new guidance on the Investigator’s Brochure (IB) for clinical trials involving advanced therapy medicinal products (ATMPs). This guidance establishes standardized requirements for documenting safety, efficacy, and manufacturing data before human studies begin—a critical step in translating cell and gene therapies from laboratory to patient care.
Key documentation requirements for ATMP Investigator’s Brochures
Essential sections mandated by Danish Medicines Agency guidance
Source: Danish Medicines Agency, 2026 | Georgian Medical Journal News
Standardizing the path to advanced therapy trials
Advanced therapy medicinal products—encompassing cell therapies, gene therapies, and tissue-engineered medicines—represent a frontier in precision medicine but demand rigorous, transparent documentation. The Danish Medicines Agency’s new IB guidance consolidates expectations across European regulators, reducing inconsistency and expediting approval timelines for sponsors.
The IB serves as the comprehensive technical dossier used by clinical trial ethics committees and competent authorities to evaluate whether a proposed human study is scientifically sound and ethically justified. For ATMPs in particular—where manufacturing variability, immunogenicity, and long-term durability remain open questions—detailed, prospective documentation is essential before dosing the first volunteer.
What must be included in an ATMP Investigator’s Brochure
The guidance mandates comprehensive reporting across multiple domains. Non-clinical data and manufacturing information form the foundation, including preclinical efficacy studies, toxicology profiles, and quality control specifications. Clinical sections must synthesize all existing human data—whether from prior trials, compassionate use, or registry studies—along with a transparent risk-benefit assessment tailored to the proposed patient population.
Particular emphasis is placed on characterization and potency assays. Unlike small-molecule drugs, cell and gene therapies exhibit inherent variability based on source material, expansion methods, and genetic modification approaches. Sponsors must now provide detailed analytical characterization demonstrating batch-to-batch consistency and establishing acceptance criteria before clinical manufacture begins.
Guidance on clinical trial conduct also requires systematic post-manufacturing safety surveillance, with particular attention to off-target effects, insertional mutagenesis (for gene therapies), and immunological reactions. This aligns the Danish framework with emerging European Medicines Agency expectations for next-generation therapeutics.
Regulatory harmonisation and practical implications
By publishing this dedicated ATMP guidance, Denmark joins a growing movement toward transparent, evidence-based standards for advanced therapies. The framework reduces sponsor uncertainty during IB preparation and provides ethics committees with a shared checklist, accelerating review cycles across European trial networks.
For academic and commercial researchers planning cell or gene therapy trials, the Danish Medicines Agency guidance offers immediate practical clarity on documentation, quality standards, and risk reporting. Integration into institutional protocols and sponsor training programmes is now a priority for centres planning ATMP studies across Northern Europe and beyond.
The Investigator’s Brochure for ATMPs must consolidate non-clinical safety data, manufacturing specifications, clinical efficacy evidence, and systematic risk-benefit analysis before any human dosing occurs—establishing a transparent, standardized foundation for regulatory and ethics review.
— Danish Medicines Agency, 2026
Key takeaways
- The Danish Medicines Agency has published new standardized guidance for Investigator’s Brochures in advanced therapy clinical trials, reducing regulatory uncertainty across Europe.
- ATMP documentation must now include detailed non-clinical data, manufacturing quality specifications, clinical safety and efficacy summaries, and prospective risk-benefit assessments.
- Emphasis on analytical characterization and batch-to-batch consistency reflects the inherent variability of cell and gene therapies compared to conventional pharmaceuticals.
- Implementation of this guidance should accelerate ethics committee review and harmonise trial approval timelines across European study networks.
Frequently asked questions
Why is an Investigator’s Brochure specifically needed for ATMPs?
Unlike synthetic drugs, cell and gene therapies exhibit biological variability inherent to living systems. An ATMP IB must document this variability through detailed characterization, potency assays, and manufacturing consistency data to establish that the therapy is sufficiently reproducible and safe for human use.
How does this Danish guidance differ from previous IB standards?
The new guidance introduces ATMP-specific requirements around manufacturing characterization, off-target risk assessment, and long-term durability data—reflecting evolving understanding of advanced therapy safety. It harmonises expectations with other European regulators, reducing inconsistency.
When should sponsors begin preparing the ATMP IB?
Preparation should begin during preclinical development, ideally in parallel with manufacturing scale-up and quality control validation. Early engagement with regulatory authorities via pre-IND (or equivalent) meetings can clarify documentation expectations and prevent costly revision cycles.
As cell and gene therapies continue to advance from bench to bedside, standardised documentation frameworks become increasingly vital to patient safety and regulatory efficiency. The Danish Medicines Agency’s new guidance establishes a clear, evidence-based foundation for sponsors, ethics committees, and national authorities to collaborate on ATMP trial initiation across Europe. Centres planning such studies are advised to integrate this guidance into their institutional protocols and sponsor engagement practices immediately.
Source: For Clinical Trials with ATMP: Guidance to the content of the Investigator’s Brochure published
